Pfizer and BioNTech said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.
Post a Comment
EmoticonClick to see the code!
To insert emoticon you must added at least one space before the code.